These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 33463455)

  • 1. Cardio-protective Effects of Glucagon-like Peptide-1 Receptor Agonists: An Overview of Systematic Reviews and Publication Overlap.
    Zafeiropoulos S; Pagiantza A; Doundoulakis I; Stalikas N; Farmakis I; Samaras A; Antza C; Giannakoulas G
    Curr Pharm Des; 2021; 27(8):1068-1079. PubMed ID: 33463455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile.
    Scheen AJ
    Expert Opin Drug Saf; 2024 Jul; 23(7):797-810. PubMed ID: 38738549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.
    Mannucci E; Dicembrini I; Nreu B; Monami M
    Diabetes Obes Metab; 2020 Feb; 22(2):203-211. PubMed ID: 31595657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.
    Sposito AC; Berwanger O; de Carvalho LSF; Saraiva JFK
    Cardiovasc Diabetol; 2018 Dec; 17(1):157. PubMed ID: 30545359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
    Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.
    Tanaka A; Node K
    Cardiovasc Diabetol; 2018 Jun; 17(1):85. PubMed ID: 29895290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
    Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
    Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients with Type 2 Diabetes Without Baseline Metformin: A Systematic Review and Update Meta-analysis.
    Lavalle-Cobo A; Masson W; Lobo M; Masson G; Molinero G
    High Blood Press Cardiovasc Prev; 2021 Nov; 28(6):605-612. PubMed ID: 34705249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
    Urquhart S; Willis S
    JAAPA; 2020 Aug; 33(8):19-30. PubMed ID: 32740122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder: Recent Updates of Clinical and Pre-clinical Evidence.
    Seksaria S; Dutta BJ; Kaur M; Gupta GD; Bodakhe SH; Singh A
    Curr Diabetes Rev; 2024; 20(6):e090823219597. PubMed ID: 37559236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of Glucagon-Like Peptide-1 Receptor Agonists to Reduce Adverse Cardiovascular Disease Events in Patients with Type 2 Diabetes Mellitus.
    Grewal S; Zaman N; Borgatta L; Nudy M; Foy AJ; Peterson B
    Am J Cardiol; 2021 Sep; 154():48-53. PubMed ID: 34266665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
    Urquhart S; Willis S
    JAAPA; 2020 Aug; 33(S8 Suppl 1):19-30. PubMed ID: 32756221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
    Brunton SA; Wysham CH
    Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?
    Hayat J; Shah NP; Agarwala A; Khan MS; Butler J
    Curr Atheroscler Rep; 2024 Aug; 26(8):341-351. PubMed ID: 38809399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The time-varying cardiovascular benefits of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus: Evidence from large multinational trials.
    Deo SV; Marsia S; McAllister DA; Elgudin Y; Sattar N; Pell JP
    Diabetes Obes Metab; 2022 Aug; 24(8):1607-1616. PubMed ID: 35491516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
    Sattar N; Lee MMY; Kristensen SL; Branch KRH; Del Prato S; Khurmi NS; Lam CSP; Lopes RD; McMurray JJV; Pratley RE; Rosenstock J; Gerstein HC
    Lancet Diabetes Endocrinol; 2021 Oct; 9(10):653-662. PubMed ID: 34425083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of glucagon-like peptide-1 receptor agonists on patients with heart failure: a meta-analysis of randomized controlled trials.
    Obata S; Miyamoto Y; Slipczuk L; Takagi H; Kuno T
    J Cardiovasc Med (Hagerstown); 2023 Feb; 24(2):132-137. PubMed ID: 36583981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.